Tiziana Life Sciences Develops a Drug that could Help to Fight COVID-19.


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Tiziana Life Sciences Develops a Drug that could Help to Fight COVID19
On the ground testing in China has revealed anti-IL6R mAbs, currently approved for rheumatoid arthritis, has a role to play in treating patients.

Tiziana Life Sciences  has said it is to “expedite development” of a drug that it believes could help COVID-19 patients with severe lung damage.

The company’s TZLS-501 is a class of monoclonal antibody (mAb) called an anti-interleukin-6 receptor, or anti-IL6R for short.

On the ground testing in China has revealed anti-IL6R mAbs, currently approved for rheumatoid arthritis, has a role to play in treating patients.

So, the country’s National Health Commission has recommended the use of Roche blockbuster, Actemra, for patients infected with COVID-19 with serious lung damage and elevated IL-6 levels.

Sanofi and Regeneron are currently exploring the use in this setting of Kevzara, another FDA-approved anti-IL-6 receptor arthritis therapy.

Tiziana, meanwhile, will start assessing the drug in patients as soon as is practicable and will administer TZLS-501 using its proprietary formulation technology.

It said the features of its drug candidate should provide it with “distinct advantages” other anti-IL-6R mAbs such as Actemra and Kevzara in treating severely affected COVID-19 patients.

The aforementioned advantages are TZLS-501’s dual mechanism of action to inhibit signalling by the membrane-bound and soluble IL-6 receptors along with the rapid depletion of circulating IL-6 cytokine, a major cause of lung damage.

“We are excited to move forward with our clinical development plan to expedite evaluation in patients as soon as possible", said Tiziana's chief executive Dr Kunwar Shailubhai.

Gabriele Cerrone, chairman, added that Tiziana only became aware of the potential of its anti-IL6R mAb at the weekend after people in Naples with lung problems caused by coronavirus started to respond to treatment with Actemra.

“ We are sitting one of best anti-IL6R monoclonal antibodies on the market but had no idea it could be used for Covid-19 complications on the respiratory system as no-one had ever tried it before.”

Source : Proactiveinvestors.com

Tags : #Tizianalifescience #Coronavirus #Rheumatoidarthritis

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026